Aurdan Capital Management LLC Makes New Investment in Amgen Inc. (NASDAQ:AMGN)

Aurdan Capital Management LLC purchased a new stake in Amgen Inc. (NASDAQ:AMGN - Free Report) during the fourth quarter, according to the company in its most recent filing with the SEC. The firm purchased 25,275 shares of the medical research company's stock, valued at approximately $6,588,000. Amgen comprises 2.5% of Aurdan Capital Management LLC's investment portfolio, making the stock its 12th biggest position.

Other institutional investors also recently made changes to their positions in the company. Centricity Wealth Management LLC acquired a new position in Amgen during the 4th quarter worth approximately $25,000. Pinney & Scofield Inc. acquired a new stake in Amgen in the fourth quarter valued at $26,000. Ritter Daniher Financial Advisory LLC DE boosted its stake in Amgen by 66.2% during the 4th quarter. Ritter Daniher Financial Advisory LLC DE now owns 128 shares of the medical research company's stock valued at $33,000 after acquiring an additional 51 shares during the last quarter. Synergy Investment Management LLC acquired a new position in Amgen during the 4th quarter worth $34,000. Finally, Atala Financial Inc bought a new stake in shares of Amgen in the 4th quarter worth about $34,000. 76.50% of the stock is owned by hedge funds and other institutional investors.

Amgen Price Performance

Shares of AMGN stock traded up $5.14 during mid-day trading on Thursday, hitting $283.54. 2,801,127 shares of the stock traded hands, compared to its average volume of 2,801,330. The company has a debt-to-equity ratio of 9.62, a quick ratio of 0.95 and a current ratio of 1.26. The firm has a market cap of $152.46 billion, a price-to-earnings ratio of 37.56, a price-to-earnings-growth ratio of 2.63 and a beta of 0.51. The company's 50-day simple moving average is $284.48 and its 200-day simple moving average is $285.76. Amgen Inc. has a twelve month low of $253.30 and a twelve month high of $346.85.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical research company reported $4.90 EPS for the quarter, topping the consensus estimate of $4.18 by $0.72. Amgen had a net margin of 12.24% and a return on equity of 176.32%. The firm had revenue of $8.15 billion for the quarter, compared to analysts' expectations of $8.05 billion. During the same period in the previous year, the business earned $3.96 earnings per share. Amgen's revenue for the quarter was up 9.4% compared to the same quarter last year. As a group, equities research analysts expect that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 6th. Investors of record on Friday, May 16th will be paid a dividend of $2.38 per share. This represents a $9.52 annualized dividend and a yield of 3.36%. The ex-dividend date of this dividend is Friday, May 16th. Amgen's dividend payout ratio is presently 86.86%.

Analyst Ratings Changes

Several brokerages have recently commented on AMGN. Piper Sandler reduced their price target on shares of Amgen from $329.00 to $328.00 and set an "overweight" rating on the stock in a research report on Friday, May 16th. UBS Group reiterated a "neutral" rating and issued a $315.00 target price (down previously from $319.00) on shares of Amgen in a research report on Friday, May 2nd. Wall Street Zen upgraded Amgen from a "buy" rating to a "strong-buy" rating in a report on Sunday, May 18th. Guggenheim assumed coverage on Amgen in a research note on Tuesday, May 20th. They set a "neutral" rating and a $288.00 price objective on the stock. Finally, Bank of America lifted their price objective on shares of Amgen from $275.00 to $294.00 and gave the stock an "underperform" rating in a report on Wednesday, March 5th. Two analysts have rated the stock with a sell rating, twelve have given a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $309.22.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.